Sovaldi In Medicaid: Contractor Molina Urges Government To Assume Up-Front Cost
Executive Summary
Medicaid managed care organization Molina says its 2014 payment rates are not adequate to cover the cost of Gilead Sciences’ hepatitis C drug Sovaldi and that the government should handle the upfront costs. WellPoint’s Medicaid plans have seen a 50% increase in the cost of treating hepatitis C patients.
You may also be interested in...
Medicaid Coverage For Gilead’s Sovaldi “Imprudent” Unless Price Reduced – Patient Group
In response to price concerns with Sovaldi, Gilead Sciences emphasized that “Medicaid, by law, receives very deep discounts, and Gilead is working with each state to complete the necessary steps to ensure a timely review and addition to the state formulary.”
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.